Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases

被引：20
|
作者：
Papamichael, Konstantinos [1 ]
Clarke, William T. [1 ]
Vande Casteele, Niels [2 ]
Germansky, Katharine A. [1 ]
Feuerstein, Joseph D. [1 ]
Melmed, Gil Y. [3 ]
Siegel, Corey A. [4 ]
Irving, Peter M. [5 ]
Cheifetz, Adam S. [1 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
[2] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[3] Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90048 USA
[4] Dartmouth Hitchcock Med Ctr, Dept Gastroenterol & Hepatol, Lebanon, NH 03766 USA
[5] Guys & St Thomas NHS Fdn Trust, Dept Gastroenterol & Hepatol, London, England
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 19卷 / 04期
关键词：
D O I：
10.1016/j.cgh.2020.03.002
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：839 / +
页数：5
相关论文
共 50 条
  • [21] Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease
    Quera, Rodrigo
    Moreno, Mauricio
    Simian, Daniela
    Ibanez, Patricio
    Lubascher, Jaime
    Figueroa, Carolina
    Flores, Lilian
    Kronberg, Udo
    Pizarro, Gonzalo
    Fluxa, Daniela
    REVISTA MEDICA DE CHILE, 2018, 146 (11) : 1241 - 1251
  • [22] Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab
    Khan, M.
    Heetun, Z.
    Moloney, J.
    Courtney, G.
    Aftab, A. R.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : S73 - S74
  • [23] Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
    Kato, Masaichi
    Sugimoto, Ken
    Ikeya, Kentaro
    Takano, Ryosuke
    Matsuura, Ai
    Miyazu, Takahiro
    Ishida, Natsuki
    Tamura, Satoshi
    Tani, Shinya
    Yamade, Mihoko
    Hamaya, Yasushi
    Iwaizumi, Moriya
    Osawa, Satoshi
    Furuta, Takahisa
    Hanai, Hiroyuki
    PLOS ONE, 2021, 16 (07):
  • [24] Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (02) : 369 - 370
  • [25] A Comparison of Combination Therapy With Infliximab or Adalimumab and an Immunosuppressive Agent Versus Monotherapy in Patients With Inflammatory Bowel Disease
    Barnes, Edward L.
    Lucci, Matthew B.
    Collins, Emily
    Cao, Bonnie
    Carrellas, Madeline
    Crowell, Anne Marie
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2015, 148 (04) : S268 - S268
  • [26] Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease
    Shannon Chang
    Stephen Hanauer
    Current Treatment Options in Gastroenterology, 2017, 15 (1) : 53 - 70
  • [27] Drug survival of infliximab and adalimumab in inflammatory bowel disease
    Asadipour, Erfan
    Kargar, Mona
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (06) : 1521 - 1523
  • [28] Drug survival of infliximab and adalimumab in inflammatory bowel disease
    Erfan Asadipour
    Mona Kargar
    International Journal of Clinical Pharmacy, 2020, 42 : 1521 - 1523
  • [29] Adalimumab or Infliximab for the Treatment of Inflammatory Bowel Disease Patients: Which Is More Effective?
    Carrillo-Ramos, Maria Jesus
    Duarte-Chang, Calixto
    Maldonado-Perez, Belen
    Beltran-Castano, Rocio
    Castro-Laria, Luisa
    Argueelles-Arias, Federico
    Benitez-Roldan, Antonio
    Caunedo-Alvarez, Angel
    Pellicer-Bautista, Francisco
    Herrerias, Juan M.
    GASTROENTEROLOGY, 2014, 146 (05) : S196 - S196
  • [30] Therapeutic drug monitoring of infliximab biosimilar and anti-infliximab antibodies in inflammatory diseases
    Elberdin, Laida
    Outeda, Maria
    Mateos, Maria
    Martinez, Cristina
    Salvador, Pilar
    Angeles Porta, Maria
    Isabel Martin, Maria
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 338 - 339
12345